BRPI0215213C1 - peptídeos com capacidade de ligação com o sítio de fosforilação por caseína quinase ii, e, composição farmacêutica - Google Patents

peptídeos com capacidade de ligação com o sítio de fosforilação por caseína quinase ii, e, composição farmacêutica

Info

Publication number
BRPI0215213C1
BRPI0215213C1 BRPI0215213A BR0215213A BRPI0215213C1 BR PI0215213 C1 BRPI0215213 C1 BR PI0215213C1 BR PI0215213 A BRPI0215213 A BR PI0215213A BR 0215213 A BR0215213 A BR 0215213A BR PI0215213 C1 BRPI0215213 C1 BR PI0215213C1
Authority
BR
Brazil
Prior art keywords
peptides
casein kinase
phosphorylation site
binding
pharmaceutical composition
Prior art date
Application number
BRPI0215213A
Other languages
English (en)
Other versions
BRPI0215213B1 (pt
BR0215213A (pt
Inventor
Moro Soria Alejandro
Santos Savio Alicia
González Barrios Belkis
Javier González López Luis
Francisco Santiago Vispo Nelson
Reyes Acosta Osvaldo
Silva Rodríguez Ricardo
Ernesto Perea Rodríguez Silvio
Puchades Izaguirre Yaquelín
Original Assignee
Ct Ingenieria Genetica Biotecnologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotecnologia filed Critical Ct Ingenieria Genetica Biotecnologia
Publication of BR0215213A publication Critical patent/BR0215213A/pt
Publication of BRPI0215213B1 publication Critical patent/BRPI0215213B1/pt
Publication of BRPI0215213C1 publication Critical patent/BRPI0215213C1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"peptídeos com capacidade de ligação com o sítio de fosforilação por caseína quinase ii, composição farmacêutica, uso dos peptídeos, e, vetor de expressão em células de mamíferos". peptídeos úteis para o tratamento de tumores de origem epitelial e especialmente aqueles associados a tipos oncogênicos de vírus papiloma (hpv). identificação de peptídeos cuja estrutura permita o bloqueio do domínio de fosforilação por caseína quinase (ckii) mediante a interação direta com referido sítio. na presente invenção mostra-se onze peptídeos com estrutura cíclica e seqüência de aminoácidos diferente, os quais inibem o sítio de fosforilação por ckii in vitro, produzem citotoxicidade em células de carcinoma de colo uterino humano transformadas por hpv-16 (caski) e, adicionalmente, incrementam a sensibilidade de referidas células ao efeito citostático do interferon (ifn). a invenção refere-se adicionalmente ao uso de moléculas miméticas tanto de origem peptídica como de origem química.
BRPI0215213A 2001-12-20 2002-12-04 peptídeos com capacidade de ligação com o sítio de fosforilação por caseína quinase ii, e, composição farmacêutica BRPI0215213C1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CU20010309A CU23225A1 (es) 2001-12-20 2001-12-20 PéPTIDOS PARA EL TRATAMIENTO DEL CáNCER ASOCIADO AL VIRUS PAPILOMA HUMANO (VPH) Y DE OTROS TUMORES EPITELIALES
CU0309/01 2001-12-20
PCT/CU2002/000010 WO2003054002A1 (es) 2001-12-20 2002-12-04 Péptidos para el tratamiento del cáncer asociado al virus papiloma humano (vph) y de otros tumores epiteliales

Publications (3)

Publication Number Publication Date
BR0215213A BR0215213A (pt) 2004-12-07
BRPI0215213B1 BRPI0215213B1 (pt) 2018-09-11
BRPI0215213C1 true BRPI0215213C1 (pt) 2021-05-25

Family

ID=40091679

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0215213A BRPI0215213C1 (pt) 2001-12-20 2002-12-04 peptídeos com capacidade de ligação com o sítio de fosforilação por caseína quinase ii, e, composição farmacêutica

Country Status (34)

Country Link
US (2) US7374767B2 (pt)
EP (2) EP1491553B1 (pt)
JP (1) JP4056476B2 (pt)
KR (1) KR100642437B1 (pt)
CN (1) CN100368431C (pt)
AR (1) AR037825A1 (pt)
AT (1) ATE520704T1 (pt)
AU (1) AU2002361922B2 (pt)
BR (1) BRPI0215213C1 (pt)
CA (1) CA2471110C (pt)
CR (1) CR7361A (pt)
CU (1) CU23225A1 (pt)
DK (1) DK1491553T3 (pt)
DO (1) DOP2002000548A (pt)
ES (1) ES2371239T3 (pt)
HK (1) HK1068901A1 (pt)
HN (1) HN2002000377A (pt)
HR (1) HRP20040663B1 (pt)
IL (2) IL162633A0 (pt)
IS (1) IS2906B (pt)
MA (1) MA27868A1 (pt)
MX (1) MXPA04005832A (pt)
MY (1) MY133530A (pt)
NO (1) NO333259B1 (pt)
NZ (1) NZ534170A (pt)
PE (1) PE20030861A1 (pt)
PT (1) PT1491553E (pt)
RU (1) RU2290410C2 (pt)
SI (1) SI1491553T1 (pt)
TN (1) TNSN04114A1 (pt)
UA (1) UA81403C2 (pt)
UY (1) UY27602A1 (pt)
WO (1) WO2003054002A1 (pt)
ZA (1) ZA200405514B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23225A1 (es) * 2001-12-20 2007-08-30 Ct Ingenieria Genetica Biotech PéPTIDOS PARA EL TRATAMIENTO DEL CáNCER ASOCIADO AL VIRUS PAPILOMA HUMANO (VPH) Y DE OTROS TUMORES EPITELIALES
CU23431B6 (es) * 2005-05-12 2009-10-16 Ct Ingenieria Genetica Biotech Método para la inhibición de la proliferación de células tumorales y el tratamiento del cáncer
GB2433740A (en) * 2005-12-23 2007-07-04 Rapid Biosensor Systems Ltd Detection of tuberculosis infection
CU23511B6 (es) 2006-02-28 2010-04-13 Biorec B V Combinación farmacéutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas
GB2441131A (en) * 2006-08-24 2008-02-27 Univ Dundee Modulation of binding of CK2a to NDPK
CN100522992C (zh) * 2007-02-12 2009-08-05 中国科学院昆明动物研究所 一种环状小肽ba
CN101641104B (zh) * 2007-03-27 2013-06-05 大幸药品株式会社 感染性皮肤和粘膜疾病治疗药
WO2010096751A1 (en) 2009-02-23 2010-08-26 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating a disease mediated by soluble oligomeric amyloid beta
AU2010223888A1 (en) * 2009-03-13 2011-10-06 Egen, Inc. Compositions and methods for the delivery of biologically active RNAs
SG11201805420SA (en) 2015-12-30 2018-07-30 Kodiak Sciences Inc Antibodies and conjugates thereof
CU20200103A7 (es) * 2020-12-18 2022-07-08 Ct Ingenieria Genetica Biotecnologia Péptido sintético para la inducción de inmunidad antitumoral y antiviral
CU20210058A7 (es) 2021-07-09 2023-02-13 Ct Ingenieria Genetica Biotecnologia Péptidos lineales que inhiben la fosforilación mediada por ck2 y composiciones que los comprenden

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE902820A1 (en) * 1989-08-07 1991-02-27 Merck & Co Inc Peptide inhibitors of human papilloma virus protein binding¹to retinoblastoma gene proteins
JPH05310784A (ja) * 1991-09-04 1993-11-22 Merck & Co Inc ヒト乳頭腫ウイルスタンパク質と網膜芽細胞腫遺伝子タンパク質との結合のペプチド阻害剤
GB9313556D0 (en) * 1993-07-01 1993-08-18 British Tech Group Synthetic peptides of human papillomavirus
US5625031A (en) * 1994-02-08 1997-04-29 Bristol-Myers Squibb Company Peptide inhibitors of the p33cdk2 and p34cdc2 cell cycle regulatory kinases and human papillomavirus E7 oncoprotein
ATE235509T1 (de) * 1998-06-30 2003-04-15 Deutsches Krebsforsch Peptide zur inhibition von hpv e7 proteinen
WO2001064835A2 (en) * 2000-02-28 2001-09-07 Hyseq, Inc. Novel nucleic acids and polypeptides
US6641994B2 (en) * 1999-08-25 2003-11-04 Pharmacia & Upjohn Company Methods of identifying anti-viral agents
CU23225A1 (es) * 2001-12-20 2007-08-30 Ct Ingenieria Genetica Biotech PéPTIDOS PARA EL TRATAMIENTO DEL CáNCER ASOCIADO AL VIRUS PAPILOMA HUMANO (VPH) Y DE OTROS TUMORES EPITELIALES

Also Published As

Publication number Publication date
RU2004122084A (ru) 2005-03-27
PE20030861A1 (es) 2003-12-02
WO2003054002A1 (es) 2003-07-03
EP2383282A1 (en) 2011-11-02
BRPI0215213B1 (pt) 2018-09-11
AR037825A1 (es) 2004-12-09
KR100642437B1 (ko) 2006-11-06
US20090005294A1 (en) 2009-01-01
MY133530A (en) 2007-11-30
ZA200405514B (en) 2005-03-30
DK1491553T3 (da) 2011-12-05
HRP20040663B1 (hr) 2013-05-31
CN100368431C (zh) 2008-02-13
CR7361A (es) 2005-02-18
TNSN04114A1 (en) 2006-06-01
MXPA04005832A (es) 2004-09-13
NZ534170A (en) 2006-08-31
KR20050002811A (ko) 2005-01-10
SI1491553T1 (sl) 2011-12-30
DOP2002000548A (es) 2003-06-30
NO20043112L (no) 2004-07-20
IL162633A (en) 2011-02-28
US7374767B2 (en) 2008-05-20
UY27602A1 (es) 2003-04-30
EP1491553B1 (en) 2011-08-17
IS7320A (is) 2004-06-16
AU2002361922A1 (en) 2003-07-09
US7947287B2 (en) 2011-05-24
IS2906B (is) 2014-11-15
RU2290410C2 (ru) 2006-12-27
CA2471110C (en) 2017-01-31
BR0215213A (pt) 2004-12-07
US20060233742A1 (en) 2006-10-19
CN1620464A (zh) 2005-05-25
NO333259B1 (no) 2013-04-22
JP2005525090A (ja) 2005-08-25
HRP20040663A2 (en) 2005-08-31
UA81403C2 (en) 2008-01-10
EP1491553A1 (en) 2004-12-29
ES2371239T3 (es) 2011-12-28
CU23225A1 (es) 2007-08-30
IL162633A0 (pt) 2005-11-20
ATE520704T1 (de) 2011-09-15
MA27868A1 (fr) 2006-05-02
JP4056476B2 (ja) 2008-03-05
HN2002000377A (es) 2003-04-10
CA2471110A1 (en) 2003-07-03
PT1491553E (pt) 2011-11-25
AU2002361922B2 (en) 2007-04-05
HK1068901A1 (en) 2005-05-06

Similar Documents

Publication Publication Date Title
BRPI0215213C1 (pt) peptídeos com capacidade de ligação com o sítio de fosforilação por caseína quinase ii, e, composição farmacêutica
Tornesello et al. Human oncoviruses and p53 tumor suppressor pathway deregulation at the origin of human cancers
Jiang et al. Development of HIV entry inhibitors targeted to the coiled-coil regions of gp41
PT593754E (pt) Peptidos do virus do papiloma humano para uso em composicoes indutoras de uma reaccao das celulas t no homem
BRPI0511196A (pt) polipeptìdeo isolado ou recombinante, conjugado, composição, célula hospedeira, vetor, métodos para preparar um polipeptìdeo, para preparar um conjugado, para reduzir o número de cópias de um vìrus em células infectadas com o vìrus, para reduzir o nìvel de rna hcv, dna hbv e rna hiv no soro de um paciente infectado com hcv, hbv e hiv, e, uso do polipeptìdeo, do conjugado ou da composição
NO20053920L (no) Preparat for og behandling av demyelineringssykdommer og paralyse ved administrering av remyelineringsmidler.
AR069903A1 (es) Conjugado anticuerpo- molecula asociada dirigidos a la proteina tirosina quinasa 7 (ptk 7), composicion farmaceutica que lo comprende, acido nucleico, factor de expresion y celula huesped relacionados y su uso para preparar un medicamento util para el tratamiento o prevencion de cancer
CU23432B6 (es) Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
WO2018120277A1 (zh) 包含f1、f3多肽的药物组合物及其在治疗hpv感染疾病中的应用
CA2579523A1 (en) Atad3a-binding molecules for treatment, detection and prevention of cancer
BR112022004058A2 (pt) Conjugados, populações de conjugados, composição farmacêutica, métodos para o tratamento de um sujeito com uma infecção viral, o tratamento profilático de uma infecção viral, para prevenir uma infecção secundária e para tratar ou prevenir uma infecção viral
Wang et al. Antitumor activity of novel chimeric peptides derived from cyclinD/CDK4 and the protein transduction domain 4
DK1079849T3 (da) Anvendelse af HMG-proteiner til fremstilling af lægemidler med cytotoksisk virkning
Ahmed et al. The role of a non-canonical JAK-STAT pathway in IFN therapy of poxvirus infection and multiple sclerosis: An example of Occam’s Broom?
Chen et al. Discovery and characterization of a novel peptide inhibitor against influenza neuraminidase
BR112022001866A2 (pt) Derivados de amida híbridos de anfotericina b
Yan et al. Mapping of the interacting domains of hepatitis C virus core protein and the double-stranded RNA-activated protein kinase PKR
US8685923B2 (en) Fibrillar albumin for use in inhibiting cancer growth
KR20200012894A (ko) 펩타이드 및 항바이러스제로서의 이의 용도
EA199900438A1 (ru) Препарат местного применения для введения пептидных лекарственных средств в живые организмы
Kristedja et al. Synthesis and antiproliferative activity of hybrid peptides for ovarian and prostate cancer
CY1112340T1 (el) Πεπτιδια για την θεραπευτικη αγωγη καρκινου που συνδεεται με τον ιο ανθρωπινων θηλωματων (hpv) και αλλων επιθηλιακων ογκων
AR014768A1 (es) Medicamento para evitar o tratar los tumores especificos de los virus del papiloma humano que contiene por lo menos una proteina de fusion de por lomenos una proteina l1 de uno o mas virus del papiloma y de por lo menos una proteina e de uno o mas virus de papiloma, un procedimiento para su preparac
Singh et al. Modulation of key signal transduction molecules by a novel peptide combination effective for the treatment of gastrointestinal carcinomas
Bolander Jr Second messengers induced by the envelope protein of a retrovirus

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/08/2018, OBSERVADAS AS CONDICOES LEGAIS. (CO) REFERENTE A RPI 2485 DE 21/08/2018, QUANTO AO TITULO.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/12/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2699 DE 27-09-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.